Last quarter (Q2 2022), Luye Pharma Group's total revenue was ¥―, a decrease of ― from the same quarter last year. In Q2, Luye Pharma Group's net income was ¥―. See Luye Pharma Group’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	-	¥ 5.20B	¥ 5.54B	¥ 6.36B	¥ 5.17B	¥ 3.81B
Cost of Revenue	-	¥ 1.80B	¥ 1.55B	¥ 1.48B	¥ 1.12B	¥ 851.48M
Gross Profit	-	¥ 3.40B	¥ 3.99B	¥ 4.88B	¥ 4.05B	¥ 2.96B
Operating Expense	-	¥ 3.11B	¥ 2.78B	¥ 3.14B	¥ 2.53B	¥ 1.87B
Operating Income	-	¥ 282.81M	¥ 1.22B	¥ 1.74B	¥ 1.52B	¥ 1.09B
Net Non Operating Interest Income Expense	-	¥ -297.46M	¥ -313.60M	¥ -196.71M	¥ -107.92M	¥ -22.82M
Other Income Expense	-	-	-	-	-	-
Pretax Income	-	¥ -74.56M	¥ 942.17M	¥ 1.63B	¥ 1.47B	¥ 1.12B
Tax Provision	-	¥ 70.23M	¥ 238.91M	¥ 279.83M	¥ 167.47M	¥ 135.76M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	¥ -134.39M	¥ 706.59M	¥ 1.40B	¥ 1.30B	¥ 981.37M
Basic EPS	-	¥ -0.04	¥ 0.22	¥ 0.46	¥ 0.41	¥ 0.30
Diluted EPS	-	¥ -0.04	¥ 0.22	¥ 0.46	¥ 0.40	¥ 0.30
Basic Average Shares	-	¥ 3.45B	¥ 3.19B	¥ 3.20B	¥ 3.21B	¥ 3.26B
Diluted Average Shares	-	¥ 3.45B	¥ 3.19B	¥ 3.36B	¥ 3.22B	¥ 3.26B
Dividend Per Share	-	¥ 0.00	¥ 0.05	¥ 0.12	¥ 0.09	¥ 0.06
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	¥ 4.92B	¥ 4.32B	¥ 4.62B	¥ 3.66B	¥ 2.72B
Net Income From Continuing And Discontinued Operation	-	¥ -134.39M	¥ 706.59M	¥ 1.40B	¥ 1.30B	¥ 981.37M
Normalized Income	-	¥ -87.83M	¥ 745.96M	¥ 1.39B	¥ 1.25B	¥ 954.99M
Interest Expense	-	¥ 399.46M	¥ 424.00M	¥ 295.46M	¥ 170.57M	¥ 50.44M
EBIT	-	¥ 324.90M	¥ 1.37B	¥ 1.93B	¥ 1.64B	¥ 1.17B
EBITDA	-	¥ 906.88M	¥ 1.88B	¥ 2.39B	¥ 1.96B	¥ 1.42B

Currency in CNY

Luye Pharma Group Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing